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To determine the incidence rate of infections with North 
American pulsed-ﬁ  eld types 7 and 8 (NAP7/NAP8) strains of 
Clostrodium difﬁ  cile, ribotype 078, and toxinotype V strains, 
we examined data collected for the Canadian Nosocomial 
Infections Surveillance Program (CNISP) CDI surveillance 
project during 2004–2008. Incidence of human infections 
increased from 0.5% in 2004/2005 to 1.6% in 2008.
C
lostridium difﬁ  cile infections (CDIs) have increased in 
incidence and severity within the past decade in North 
America and Europe (1), in large part because of the emer-
gence of the hypervirulent North American pulsed-ﬁ  eld 
type 1 (NAP1/027/III) strains (2–5). Recently, interest has 
increased in the ribotype 078 strain. A 2007 North Ameri-
can study showed that ribotype 078 strains predominated in 
swine and cattle (83%–94% prevalence), but were rare in 
a group of hospitalized persons (4% prevalence) (6). How-
ever, in studies from Europe and the United States, 078/V 
strains were found at a prevalence ranging from 3% to 11% 
(7–9). In a subsequent study by the US group, analysis of 
the toxinotype V strains from humans and food animals 
showed that 83% of strains were either NAP7 or NAP8 
(10). A Dutch group has recently shown that 078/V strains 
increased from 3% to 13% during February 2005–2008 
and can be considered hypervirulent (11). Our study aimed 
to determine the incidence rate of infections attributed to 
hypervirulent NAP7/078/V and NAP8/078/V strains of C. 
difﬁ  cile in hospitals in Canada.
The Study
The Canadian Nosocomial Infection Surveillance Pro-
gram is a collaborative effort between the Canadian Hospital 
Epidemiology Committee, a subcommittee of the Associa-
tion of Medical Microbiology and Infectious Disease Can-
ada, the Centre for Infectious Disease Prevention and Con-
trol, and the National Microbiology Laboratory of the Public 
Health Agency of Canada. The Canadian Nosocomial Infec-
tion Surveillance Program conducted prospective surveil-
lance including collection of stool specimens from patients 
showing the presence of CDI during November 2004–April 
2005 and during March and April in 2007 and 2008.
An infection was considered healthcare-associated 
CDI  if the patient’s symptoms occurred at least 72 hours 
after hospital admission or if the symptoms resulted in re-
admission of a patient who had been hospitalized within the 
2 months before the symptom onset date and who was not 
a resident in a long-term care facility or nursing home (12). 
An infection was considered community-onset CDI  if the 
healthcare-associated deﬁ  nition was not met. Outcomes 30 
days postinfection were recorded to capture severe cases, 
which were deﬁ  ned as infections in patients admitted to an 
intensive care unit, in patients who had undergone colec-
tomy, or in patients who had died (12). Deaths were as-
sessed by the Canadian Hospital Epidemiology Committee 
member and categorized into 3 groups: 1) death directly 
attributable to CDI, 2) death indirectly related to CDI by 
exacerbation of an existing disease condition, or 3) death 
not a result of CDI. The assessment was made from infor-
mation obtained from medical charts, nurse logs, laboratory 
reports, and consultation with nursing and medical staff.
All stool specimens were cultured for C. difﬁ  cile, and 
isolates were analyzed by PCR and pulsed-ﬁ  eld gel electro-
phoresis (PFGE) at the National Microbiology Laboratory. 
PFGE, ribotyping, and toxinotyping were performed as de-
scribed (10,11). MICs were determined by agar dilution or 
Etest. The primers used for PCR and sequencing are listed 
in Table 1. Macrorestriction patterns were analyzed with 
BioNumerics V4.5 (Applied Maths, Sint-Martens-Latem, 
Belgium).
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Fifteen NAP7 and 4 NAP8 patterns were identiﬁ  ed 
from isolates obtained from 2,794 patients (overall preva-
lence 0.68%). Table 2 lists the patients and epidemiologic 
information, and the Figure shows the corresponding ge-
nomic ﬁ  ngerprint patterns. During the study period, the 
incidence rate increased as follows: 8/1,785 (0.5%) in 
2004–2005; 5/638 (0.8%) in 2007; and 6/371 (1.6%) in 
2008. Of the 19 patients identiﬁ  ed, 14 were men with an 
average age of 70.8 years (not including 1 pediatric case), 
and 4 were women with an average age of 52.2 years; the 
overall average age was 61.5 years (Table 2). CDI was 
considered as community onset in 7 (37%) of 19 cases, 
and severe CDI was manifested in 3 (15.8%) case-patients 
(1 was healthcare-associated CDI  and 2 were community-
onset CDI). At 30 days postinfection for CDI, 26.3% of all 
patients had died, 1 death a direct result of CDI (5.3%), and 
1 indirectly related; 10.6% of total deaths were attributable 
to CDI.
Sequence analysis of the tcdC gene showed that all 
strains carried a C184T transition that introduces a stop 
codon leading to a presumptive truncated protein of 61 
residues, and a 39-bp deletion located downstream of the 
alternative stop codon. This tcdC variant has been pre-
viously described for toxinotype V strains (13). Sixteen 
of the isolates were ribotype 078 and 3 isolates had un-
known ribotypes. All 2004/2005 and 2007 isolates were 
toxinotype V. The 2008 isolates were not toxinotyped. 
All 19 strains were susceptible to metronidazole and van-
comycin. Seven isolates were susceptible to clindamycin 
(MIC <8 μg/mL) and 12 were resistant (6 had MICs = 8, 
2 had MICs = 16, and 4 had MICs >256). Only the 4 latter 
strains carried ermB and all were NAP8. Fourteen isolates 
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Table 1. Primers used in study of hospitalized patients with Clostridium difficile infection, Canada, 2004–2008  
Primer Sequence  (5ƍ o 3ƍ) Specificity 
tcd3 TGCAATTATAAAAACATCTTTAAAC  tcdC PaLoc negative regulator 
tcd4 TATATCTAATAAAAGGGAGATTG 
cdtB-F1 TGGACAGGAAGAATAATTCCTTC  cdtB binary toxin subunit B 
cdtB-R1 TGCAACTAACGGATCTCTTGC 
E5 CTCAAAACTTTTTAACGAGTG  ermB erythromycin/clindamycin resistance 
E6 CCTCCCGTTAAATAATAGATA 
GyrAF  TTGAAATAGCGGAAGAAATGA  gyrA DNA gyrase subunit A 
GyrAR  TTGCAGCTGTAGGGAAATC 
GyrBF  GAAGGTCAAACTAAAACAAA  gyrB DNA gyrase subunit B 
GyrBR  GGGCTCCATCTACATCG 
Table 2. Epidemiologic information from hospitalized patients with Clostridium difficile infection, Canada, 2004–2008* 
Year and patient ID  Province Age, y/sex  Source   Severe CDI†  Outcome‡ 
2004–2005 
 O1-0059  Ontario  62/M Healthcare-associated  No Discharged
 O2-0053  Ontario  35/M Community-onset  No Died-not  attrib 
 O3-0042  Ontario  64/F  Community-onset  No Discharged
 Q1-0028  Quebec  66/M Healthcare-associated  Yes  Died-attrib 
 H1-0040  Nova  Scotia  70/M Healthcare-associated  No Discharged
 S1-0054  Saskatchewan  72/M Community-onset  No Discharged
 S1-0063  Saskatchewan  82/M Community-onset  Yes  Discharged
 O7-0121  Ontario  74/M Healthcare-associated  No Survived-hosp
2007 
 O1-7-0011  Ontario  87/M Community-onset  No Survived-hosp
 O4-7-0011  Ontario  82/M Community-onset  Yes  Died-contrib 
 Q1-7-0017  Quebec  40/F  Healthcare-associated  No Discharged
 O8B-7-0002  Ontario  65/M Healthcare-associated  No Died-not  attrib 
 Q5-7-0013  Quebec  71/M Healthcare-associated  No Discharged
2008 
 B1-8-0052  British  Columbia  44/F  Healthcare-associated  No Discharged
 B1-8-0059  British  Columbia  73/M Healthcare-associated  No Discharged
 A3-8-0022  Alberta 38/F  Community-onset  No Discharged
 O2B-8-0015  Ontario  75/F  Community-onset  No Survived-hosp
 Q1-8-0008  Quebec  81/M Healthcare-associated  No Died-not  attrib 
 O5-8-0001  Ontario  2/M Healthcare-associated  No Discharged
*ID, identification; CDI, Clostridium difficile infection; Died-not attrib, death not attributable to CDI; Died-attrib, death directly attributable to CDI; Survived-
hosp, patient survived but was still in a hospital at endpoint; Died-contrib, CDI indirectly contributed to death. 
†Required admission to intensive care unit due to CDI, received a colectomy, or died. 
‡At 30 days after diagnosis of CDI.  that were susceptible to moxiﬂ  oxacin (MIC <8 μg/mL) 
had identical gyrA and gyrB quinolone-resistance–de-
termining regions (QRDR) sequences to the genes in C. 
difﬁ  cile 630 (GenBank accession no. AM180355). Five 
moxiﬂ  oxacin-resistant isolates (MIC  > 8 μg/mL) had no 
mutations in the gyrB QRDR but each had 1 mutation in 
the gyrA QRDR. One with MIC = 8 had an Asp71Val 
mutation; 3 with MIC = 16 and 1 with MIC >32 had a 
Thr82Ile mutation. These mutations have been previously 
described in moxiﬂ  oxacin-resistant C. difﬁ  cile (14).
Conclusions
C. difﬁ  cile NAP7 and NAP8/078/V strains are rela-
tively rare in hospitalized patients with CDI in Canada, 
in contrast to their prevalence in Europe and the United 
States (7–11). However, incidence rates have tripled from 
0.5% in 2004 to 1.6% in 2008 (p = 0.22). There was a high 
association with a community onset, although dataset was 
too small to statistically conﬁ  rm that increased cases were 
more likely to be community onset; 2 (40%) of 5 deaths 
were attributable to CDI. Although the number of strains 
studied here was small, data are consistent with other stud-
ies that indicate a community association for NAP7 and 
NAP8/078/V strains (9–11). The prevalence of these strains 
in Canada may be higher than suggested here if they are a 
common cause of community-associated CDI, as studies 
have indicated (10,11). The role of animals in acquisition 
of NAP7 and NAP8/078/V strains was not evaluated be-
cause animal and food contact data were not available. 
Molecular typing of C. difﬁ  cile is typically performed 
by using ribotyping in Europe and PFGE/macrorestriction 
analysis in North America; both groups may use toxinotyp-
ing, which strictly looks at PaLoc variation. We showed a 
high correlation between NAP7, NAP8, ribotype 078, and 
toxinotype V strains by the 3 typing methods, which en-
abled results of separate studies to be compared. Further-
more, tcdC analysis provides an additional diagnostic tool 
for these strains because the gene has a 39-bp deletion and 
a C184T-transition in all isolates we studied. 
Continued surveillance is warranted in humans, ani-
mals, and retail meat to determine whether NAP7 and 
8/078/V strains will continue to emerge in patients hospi-
talized in Canada and to determine whether the sources of 
these infections are related to animals or food. Surveillance 
is especially important given that these strains appear to be 
hypervirulent as has been reported for NAP1/027/III strains 
(11). 
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Figure. Dendrogram analysis of macrorestriction patterns (SmaI) 
of the NAP7 and NAP8 Clostridium difﬁ  cile strains isolated from 
the patients listed in Table 2. C. difﬁ  cile N07-00380 is a ribotype 
078 control strain. C. difﬁ  cile NAP7-CDC and NAP8-CDC control 
strains are toxinotype V. Isolates exhibiting high-level clindamycin 
resistance (>256 μg/mL) and harboring ermB are indicated. 
The amino acid change found in the gyrA protein is shown for 
the moxiﬂ   oxacin-resistant strain antimicrobial drug–resistance 
mechanisms.Hypervirulent C. difﬁ  cile Strains, Canada
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